Quantitative imaging for better outcomes
Welcome to the website of the Vogel-Claussen Heart and Lung Imaging Lab in the Institute for Diagnostic and Interventional Radiology at Hannover Medical School.
The team develops innovative, quantitative imaging markers for improved patient care. We focus on pioneering and maturing innovative techniques and imaging biomarkers for the assessment of lung and cardiovascular function and microstructure to establish novel endpoints in clinical trials. We create fully automated pipelines for the extraction of high-yield imaging biomarkers for large scale trials and clinical translation.
Our vision is to gain new insights into cardiovascular and pulmonary diseases to improve patient outcome.
Prof. Dr. med. Jens Vogel-Claussen
Dr. Kaireit has been included in the Program of Hannover Medical School for clinician scientists (PRACTIS), a new clinician scienctist program funded by the German Research Foundation (DFG). PRACTIS provides 18 months scientific exemption and a grant with a volume of €27.000.
The Röntgen society of Lower Saxony, Bremen and Saxony-Anhalt has awarded Agilo Kern, physicist of Vogel-Claussen Imaging Lab, the Hans Meyer stipend for his work "Evaluation of ventilation, perfusion and structure of the lung in paediatric CF patients using 129Xe MRI". The award ceremony took place at this year's Radiology Congress North in Hamburg. Image: courtesy of Conventus Congressmanagement & Marketing GmbH.
We thank our collaborators at Hannover Medical School (Dept. of Respiratory Medicine, Dept. of Cardiology, Dept. of Cardiac, Thoracic, Transplantation, and Vascular Surgery, Department of Pediatric Pneumology, Allergology and Neonatology, Department of Nuclear Medicine, Department of Pathology), in Hannover (Fraunhofer ITEM, CHERH) in Germany (Gießen University, Heidelberg University, LMU Munich, Mainz University, Regensburg University), Europe (Sheffield University, Erasmus University Rotterdam, AKH Vienna, Amsterdam UMC, University Hospital Zurich) and overseas (Columbia University, Johns Hopkins Medical School, University of Toronto) as well as our funding sources (DZL, BMBF, NIH, IFB-Tx, DFG, REBIRTH, foundations and industry) for successful translational research and continued support.